GT Medical Technologies raises $100M Series E for brain tumor radiation therapy
Summary
GT Medical Technologies raised $100 million in Series E funding led by Viking Global Investors. The Tempe, Arizona-based company develops GammaTile, an FDA-cleared bioabsorbable collagen implant embedded with radiation seeds that delivers targeted radiation therapy directly to the surgical cavity following brain tumor removal. Proceeds will accelerate commercial investments following the company's ROADS pivotal trial.
Why it matters
GammaTile represents a significant advancement in neuro-oncology by providing immediate, localized radiation at the time of tumor resection, potentially improving outcomes for patients with operable brain tumors including glioblastoma. The oversubscribed Series E reflects strong investor confidence in the commercial trajectory of this differentiated approach to brain cancer treatment.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial